Physician profile
Rakesh Kumar Gupta
NPI 1366495780
$1,937.88
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $44.37 · 2021: $475 · 2022: $188 · 2023: $397 · 2024: $172 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $545.15 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.21 | 2019-2024 | Jardiance |
| Inari Medical, INC. | $159.18 | 2021 | |
| Dexcom, INC. | $115.56 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $114.76 | 2019 | |
| Alnylam Pharmaceuticals INC. | $106.62 | 2022-2024 | Amvuttra |
| Gilead Sciences, INC. | $83.63 | 2019 | |
| Abbvie INC. | $70.90 | 2021-2025 | |
| Allergan, INC. | $44.37 | 2020 | |
| Novo Nordisk INC | $42.70 | 2024-2025 | Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $39.03 | 2023 | Assure Wcd |
| Pfizer INC. | $31.14 | 2019 | |
| Esperion Therapeutics, INC. | $29.61 | 2025 | Nexletol |
| Lilly USA, LLC | $27.63 | 2023 | Mounjaro |
| Astellas Pharma US INC | $26.12 | 2025 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2021 | |
| Abbott Laboratories | $19.04 | 2025 | Merlin@Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.